Who are the key players in the viral vector cdmo market?

Some of the key players are Companies, Thermo Fisher Scientific, Charles River Laboratories, Porton Advanced Solutions, Others.

BUY CHAPTERS

Global Viral Vector CDMO Market Research Report 2022

Q: How big is the viral vector cdmo market?

HighlightsThe global Viral Vector CDMO market is projected to reach US million by 2028 from an estimated US million in 2022 at a CAGR of during 2023 and 2028.North American market for Viral Vector CDMO is estimated to increase from million in 2022 to reach million by 2028 at a CAGR of during the forecast period of 2023 through 2028.AsiaPacific market for Viral Vector CDMO is estimated to increase from million in 2022 to reach million by 2028 at a CAGR of during the forecast period of 2022 through 2028.The global market for Viral Vector CDMO in Biopharmaceutical Company is estimated to increase from million in 2022 to million by 2028 at a CAGR of during the forecast period of 2022 through 2028.The major global companies of Viral Vector CDMO include Thermo Fisher Scientific GenScript ProBio Hillgene Charles River Laboratories Ubrigene Obio Technology shanghai Genesail Biotech Shanghai WuXi ATU and Porton Advanced Solutions e. category - Medical Care

Code: QYRE-Auto-4A12824

Report

December 2022

Pages:116

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Viral Vector CDMO Market

The global Viral Vector CDMO market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.

North American market for Viral Vector CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

Asia-Pacific market for Viral Vector CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The global market for Viral Vector CDMO in Biopharmaceutical Company is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The major global companies of Viral Vector CDMO include Thermo Fisher Scientific, GenScript ProBio, Hillgene, Charles River Laboratories, Ubrigene, Obio Technology (shanghai), Genesail Biotech (Shanghai), WuXi ATU and Porton Advanced Solutions, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.

Considering the economic change due to COVID-19, IIT Grade, which accounted for % of the global market of Viral Vector CDMO in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.

This report aims to provide a comprehensive presentation of the global market for Viral Vector CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector CDMO.

The Viral Vector CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Viral Vector CDMO market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Viral Vector CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

By Company

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Thermo Fisher Scientific
GenScript ProBio
Hillgene
Charles River Laboratories
Ubrigene
Obio Technology (shanghai)
Genesail Biotech (Shanghai)
WuXi ATU
Porton Advanced Solutions
Pharmaron
Asymchem Laboratories (Tianjin)
Merck
VectorBuilder
Yposkesi
Flash Therapeutics
VIVEBiotech
Miltenyi Bioindustry
Genezen
Miltenyi Biotec
Exthera
Catalent

By Type

IIT Grade
IND Grade
Clinical Trial Grade
Commercial Production Grade

By Application

Biopharmaceutical Company
Academic Scientific Research Institution

By Region

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Viral Vector CDMO Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 IIT Grade

1.2.3 IND Grade

1.2.4 Clinical Trial Grade

1.2.5 Commercial Production Grade

1.3 Market by Application

1.3.1 Global Viral Vector CDMO Market Share by Application: 2017 VS 2021 VS 2028

1.3.2 Biopharmaceutical Company

1.3.3 Academic Scientific Research Institution

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Viral Vector CDMO Market Perspective (2017-2028)

2.2 Viral Vector CDMO Growth Trends by Region

2.2.1 Viral Vector CDMO Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Viral Vector CDMO Historic Market Size by Region (2017-2022)

2.2.3 Viral Vector CDMO Forecasted Market Size by Region (2023-2028)

2.3 Viral Vector CDMO Market Dynamics

2.3.1 Viral Vector CDMO Industry Trends

2.3.2 Viral Vector CDMO Market Drivers

2.3.3 Viral Vector CDMO Market Challenges

2.3.4 Viral Vector CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Viral Vector CDMO Players by Revenue

3.1.1 Global Top Viral Vector CDMO Players by Revenue (2017-2022)

3.1.2 Global Viral Vector CDMO Revenue Market Share by Players (2017-2022)

3.2 Global Viral Vector CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Viral Vector CDMO Revenue

3.4 Global Viral Vector CDMO Market Concentration Ratio

3.4.1 Global Viral Vector CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Viral Vector CDMO Revenue in 2021

3.5 Viral Vector CDMO Key Players Head office and Area Served

3.6 Key Players Viral Vector CDMO Product Solution and Service

3.7 Date of Enter into Viral Vector CDMO Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Viral Vector CDMO Breakdown Data by Type

4.1 Global Viral Vector CDMO Historic Market Size by Type (2017-2022)

4.2 Global Viral Vector CDMO Forecasted Market Size by Type (2023-2028)

5 Viral Vector CDMO Breakdown Data by Application

5.1 Global Viral Vector CDMO Historic Market Size by Application (2017-2022)

5.2 Global Viral Vector CDMO Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America Viral Vector CDMO Market Size (2017-2028)

6.2 North America Viral Vector CDMO Market Size by Country (2017-2022)

6.3 North America Viral Vector CDMO Market Size by Country (2023-2028)

6.4 United States

6.5 Canada

7 Europe

7.1 Europe Viral Vector CDMO Market Size (2017-2028)

7.2 Europe Viral Vector CDMO Market Size by Country (2017-2022)

7.3 Europe Viral Vector CDMO Market Size by Country (2023-2028)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Viral Vector CDMO Market Size (2017-2028)

8.2 Asia-Pacific Viral Vector CDMO Market Size by Country (2017-2022)

8.3 Asia-Pacific Viral Vector CDMO Market Size by Country (2023-2028)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

9 Latin America

9.1 Latin America Viral Vector CDMO Market Size (2017-2028)

9.2 Latin America Viral Vector CDMO Market Size by Country (2017-2022)

9.3 Latin America Viral Vector CDMO Market Size by Country (2023-2028)

9.4 Mexico

9.5 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Viral Vector CDMO Market Size (2017-2028)

10.2 Middle East & Africa Viral Vector CDMO Market Size by Country (2017-2022)

10.3 Middle East & Africa Viral Vector CDMO Market Size by Country (2023-2028)

10.4 Turkey

10.5 Saudi Arabia

10.6 UAE

11 Key Players Profiles

11.1 Thermo Fisher Scientific

11.1.1 Thermo Fisher Scientific Company Detail

11.1.2 Thermo Fisher Scientific Business Overview

11.1.3 Thermo Fisher Scientific Viral Vector CDMO Introduction

11.1.4 Thermo Fisher Scientific Revenue in Viral Vector CDMO Business (2017-2022)

11.1.5 Thermo Fisher Scientific Recent Development

11.2 GenScript ProBio

11.2.1 GenScript ProBio Company Detail

11.2.2 GenScript ProBio Business Overview

11.2.3 GenScript ProBio Viral Vector CDMO Introduction

11.2.4 GenScript ProBio Revenue in Viral Vector CDMO Business (2017-2022)

11.2.5 GenScript ProBio Recent Development

11.3 Hillgene

11.3.1 Hillgene Company Detail

11.3.2 Hillgene Business Overview

11.3.3 Hillgene Viral Vector CDMO Introduction

11.3.4 Hillgene Revenue in Viral Vector CDMO Business (2017-2022)

11.3.5 Hillgene Recent Development

11.4 Charles River Laboratories

11.4.1 Charles River Laboratories Company Detail

11.4.2 Charles River Laboratories Business Overview

11.4.3 Charles River Laboratories Viral Vector CDMO Introduction

11.4.4 Charles River Laboratories Revenue in Viral Vector CDMO Business (2017-2022)

11.4.5 Charles River Laboratories Recent Development

11.5 Ubrigene

11.5.1 Ubrigene Company Detail

11.5.2 Ubrigene Business Overview

11.5.3 Ubrigene Viral Vector CDMO Introduction

11.5.4 Ubrigene Revenue in Viral Vector CDMO Business (2017-2022)

11.5.5 Ubrigene Recent Development

11.6 Obio Technology (shanghai)

11.6.1 Obio Technology (shanghai) Company Detail

11.6.2 Obio Technology (shanghai) Business Overview

11.6.3 Obio Technology (shanghai) Viral Vector CDMO Introduction

11.6.4 Obio Technology (shanghai) Revenue in Viral Vector CDMO Business (2017-2022)

11.6.5 Obio Technology (shanghai) Recent Development

11.7 Genesail Biotech (Shanghai)

11.7.1 Genesail Biotech (Shanghai) Company Detail

11.7.2 Genesail Biotech (Shanghai) Business Overview

11.7.3 Genesail Biotech (Shanghai) Viral Vector CDMO Introduction

11.7.4 Genesail Biotech (Shanghai) Revenue in Viral Vector CDMO Business (2017-2022)

11.7.5 Genesail Biotech (Shanghai) Recent Development

11.8 WuXi ATU

11.8.1 WuXi ATU Company Detail

11.8.2 WuXi ATU Business Overview

11.8.3 WuXi ATU Viral Vector CDMO Introduction

11.8.4 WuXi ATU Revenue in Viral Vector CDMO Business (2017-2022)

11.8.5 WuXi ATU Recent Development

11.9 Porton Advanced Solutions

11.9.1 Porton Advanced Solutions Company Detail

11.9.2 Porton Advanced Solutions Business Overview

11.9.3 Porton Advanced Solutions Viral Vector CDMO Introduction

11.9.4 Porton Advanced Solutions Revenue in Viral Vector CDMO Business (2017-2022)

11.9.5 Porton Advanced Solutions Recent Development

11.10 Pharmaron

11.10.1 Pharmaron Company Detail

11.10.2 Pharmaron Business Overview

11.10.3 Pharmaron Viral Vector CDMO Introduction

11.10.4 Pharmaron Revenue in Viral Vector CDMO Business (2017-2022)

11.10.5 Pharmaron Recent Development

11.11 Asymchem Laboratories (Tianjin)

11.11.1 Asymchem Laboratories (Tianjin) Company Detail

11.11.2 Asymchem Laboratories (Tianjin) Business Overview

11.11.3 Asymchem Laboratories (Tianjin) Viral Vector CDMO Introduction

11.11.4 Asymchem Laboratories (Tianjin) Revenue in Viral Vector CDMO Business (2017-2022)

11.11.5 Asymchem Laboratories (Tianjin) Recent Development

11.12 Merck

11.12.1 Merck Company Detail

11.12.2 Merck Business Overview

11.12.3 Merck Viral Vector CDMO Introduction

11.12.4 Merck Revenue in Viral Vector CDMO Business (2017-2022)

11.12.5 Merck Recent Development

11.13 VectorBuilder

11.13.1 VectorBuilder Company Detail

11.13.2 VectorBuilder Business Overview

11.13.3 VectorBuilder Viral Vector CDMO Introduction

11.13.4 VectorBuilder Revenue in Viral Vector CDMO Business (2017-2022)

11.13.5 VectorBuilder Recent Development

11.14 Yposkesi

11.14.1 Yposkesi Company Detail

11.14.2 Yposkesi Business Overview

11.14.3 Yposkesi Viral Vector CDMO Introduction

11.14.4 Yposkesi Revenue in Viral Vector CDMO Business (2017-2022)

11.14.5 Yposkesi Recent Development

11.15 Flash Therapeutics

11.15.1 Flash Therapeutics Company Detail

11.15.2 Flash Therapeutics Business Overview

11.15.3 Flash Therapeutics Viral Vector CDMO Introduction

11.15.4 Flash Therapeutics Revenue in Viral Vector CDMO Business (2017-2022)

11.15.5 Flash Therapeutics Recent Development

11.16 VIVEBiotech

11.16.1 VIVEBiotech Company Detail

11.16.2 VIVEBiotech Business Overview

11.16.3 VIVEBiotech Viral Vector CDMO Introduction

11.16.4 VIVEBiotech Revenue in Viral Vector CDMO Business (2017-2022)

11.16.5 VIVEBiotech Recent Development

11.17 Miltenyi Bioindustry

11.17.1 Miltenyi Bioindustry Company Detail

11.17.2 Miltenyi Bioindustry Business Overview

11.17.3 Miltenyi Bioindustry Viral Vector CDMO Introduction

11.17.4 Miltenyi Bioindustry Revenue in Viral Vector CDMO Business (2017-2022)

11.17.5 Miltenyi Bioindustry Recent Development

11.18 Genezen

11.18.1 Genezen Company Detail

11.18.2 Genezen Business Overview

11.18.3 Genezen Viral Vector CDMO Introduction

11.18.4 Genezen Revenue in Viral Vector CDMO Business (2017-2022)

11.18.5 Genezen Recent Development

11.19 Miltenyi Biotec

11.19.1 Miltenyi Biotec Company Detail

11.19.2 Miltenyi Biotec Business Overview

11.19.3 Miltenyi Biotec Viral Vector CDMO Introduction

11.19.4 Miltenyi Biotec Revenue in Viral Vector CDMO Business (2017-2022)

11.19.5 Miltenyi Biotec Recent Development

11.20 Exthera

11.20.1 Exthera Company Detail

11.20.2 Exthera Business Overview

11.20.3 Exthera Viral Vector CDMO Introduction

11.20.4 Exthera Revenue in Viral Vector CDMO Business (2017-2022)

11.20.5 Exthera Recent Development

11.21 Catalent

11.21.1 Catalent Company Detail

11.21.2 Catalent Business Overview

11.21.3 Catalent Viral Vector CDMO Introduction

11.21.4 Catalent Revenue in Viral Vector CDMO Business (2017-2022)

11.21.5 Catalent Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global Viral Vector CDMO Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028

Table 2. Key Players of IIT Grade

Table 3. Key Players of IND Grade

Table 4. Key Players of Clinical Trial Grade

Table 5. Key Players of Commercial Production Grade

Table 6. Global Viral Vector CDMO Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028

Table 7. Global Viral Vector CDMO Market Size by Region (US$ Million): 2017 VS 2021 VS 2028

Table 8. Global Viral Vector CDMO Market Size by Region (2017-2022) & (US$ Million)

Table 9. Global Viral Vector CDMO Market Share by Region (2017-2022)

Table 10. Global Viral Vector CDMO Forecasted Market Size by Region (2023-2028) & (US$ Million)

Table 11. Global Viral Vector CDMO Market Share by Region (2023-2028)

Table 12. Viral Vector CDMO Market Trends

Table 13. Viral Vector CDMO Market Drivers

Table 14. Viral Vector CDMO Market Challenges

Table 15. Viral Vector CDMO Market Restraints

Table 16. Global Viral Vector CDMO Revenue by Players (2017-2022) & (US$ Million)

Table 17. Global Viral Vector CDMO Market Share by Players (2017-2022)

Table 18. Global Top Viral Vector CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector CDMO as of 2021)

Table 19. Ranking of Global Top Viral Vector CDMO Companies by Revenue (US$ Million) in 2021

Table 20. Global 5 Largest Players Market Share by Viral Vector CDMO Revenue (CR5 and HHI) & (2017-2022)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players Viral Vector CDMO Product Solution and Service

Table 23. Date of Enter into Viral Vector CDMO Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Viral Vector CDMO Market Size by Type (2017-2022) & (US$ Million)

Table 26. Global Viral Vector CDMO Revenue Market Share by Type (2017-2022)

Table 27. Global Viral Vector CDMO Forecasted Market Size by Type (2023-2028) & (US$ Million)

Table 28. Global Viral Vector CDMO Revenue Market Share by Type (2023-2028)

Table 29. Global Viral Vector CDMO Market Size by Application (2017-2022) & (US$ Million)

Table 30. Global Viral Vector CDMO Revenue Market Share by Application (2017-2022)

Table 31. Global Viral Vector CDMO Forecasted Market Size by Application (2023-2028) & (US$ Million)

Table 32. Global Viral Vector CDMO Revenue Market Share by Application (2023-2028)

Table 33. North America Viral Vector CDMO Market Size by Country (2017-2022) & (US$ Million)

Table 34. North America Viral Vector CDMO Market Size by Country (2023-2028) & (US$ Million)

Table 35. Europe Viral Vector CDMO Market Size by Country (2017-2022) & (US$ Million)

Table 36. Europe Viral Vector CDMO Market Size by Country (2023-2028) & (US$ Million)

Table 37. Asia-Pacific Viral Vector CDMO Market Size by Region (2017-2022) & (US$ Million)

Table 38. Asia-Pacific Viral Vector CDMO Market Size by Region (2023-2028) & (US$ Million)

Table 39. Latin America Viral Vector CDMO Market Size by Country (2017-2022) & (US$ Million)

Table 40. Latin America Viral Vector CDMO Market Size by Country (2023-2028) & (US$ Million)

Table 41. Middle East & Africa Viral Vector CDMO Market Size by Country (2017-2022) & (US$ Million)

Table 42. Middle East & Africa Viral Vector CDMO Market Size by Country (2023-2028) & (US$ Million)

Table 43. Thermo Fisher Scientific Company Detail

Table 44. Thermo Fisher Scientific Business Overview

Table 45. Thermo Fisher Scientific Viral Vector CDMO Product

Table 46. Thermo Fisher Scientific Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 47. Thermo Fisher Scientific Recent Development

Table 48. GenScript ProBio Company Detail

Table 49. GenScript ProBio Business Overview

Table 50. GenScript ProBio Viral Vector CDMO Product

Table 51. GenScript ProBio Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 52. GenScript ProBio Recent Development

Table 53. Hillgene Company Detail

Table 54. Hillgene Business Overview

Table 55. Hillgene Viral Vector CDMO Product

Table 56. Hillgene Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 57. Hillgene Recent Development

Table 58. Charles River Laboratories Company Detail

Table 59. Charles River Laboratories Business Overview

Table 60. Charles River Laboratories Viral Vector CDMO Product

Table 61. Charles River Laboratories Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 62. Charles River Laboratories Recent Development

Table 63. Ubrigene Company Detail

Table 64. Ubrigene Business Overview

Table 65. Ubrigene Viral Vector CDMO Product

Table 66. Ubrigene Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 67. Ubrigene Recent Development

Table 68. Obio Technology (shanghai) Company Detail

Table 69. Obio Technology (shanghai) Business Overview

Table 70. Obio Technology (shanghai) Viral Vector CDMO Product

Table 71. Obio Technology (shanghai) Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 72. Obio Technology (shanghai) Recent Development

Table 73. Genesail Biotech (Shanghai) Company Detail

Table 74. Genesail Biotech (Shanghai) Business Overview

Table 75. Genesail Biotech (Shanghai) Viral Vector CDMO Product

Table 76. Genesail Biotech (Shanghai) Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 77. Genesail Biotech (Shanghai) Recent Development

Table 78. WuXi ATU Company Detail

Table 79. WuXi ATU Business Overview

Table 80. WuXi ATU Viral Vector CDMO Product

Table 81. WuXi ATU Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 82. WuXi ATU Recent Development

Table 83. Porton Advanced Solutions Company Detail

Table 84. Porton Advanced Solutions Business Overview

Table 85. Porton Advanced Solutions Viral Vector CDMO Product

Table 86. Porton Advanced Solutions Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 87. Porton Advanced Solutions Recent Development

Table 88. Pharmaron Company Detail

Table 89. Pharmaron Business Overview

Table 90. Pharmaron Viral Vector CDMO Product

Table 91. Pharmaron Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 92. Pharmaron Recent Development

Table 93. Asymchem Laboratories (Tianjin) Company Detail

Table 94. Asymchem Laboratories (Tianjin) Business Overview

Table 95. Asymchem Laboratories (Tianjin) Viral Vector CDMOProduct

Table 96. Asymchem Laboratories (Tianjin) Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 97. Asymchem Laboratories (Tianjin) Recent Development

Table 98. Merck Company Detail

Table 99. Merck Business Overview

Table 100. Merck Viral Vector CDMOProduct

Table 101. Merck Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 102. Merck Recent Development

Table 103. VectorBuilder Company Detail

Table 104. VectorBuilder Business Overview

Table 105. VectorBuilder Viral Vector CDMOProduct

Table 106. VectorBuilder Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 107. VectorBuilder Recent Development

Table 108. Yposkesi Company Detail

Table 109. Yposkesi Business Overview

Table 110. Yposkesi Viral Vector CDMOProduct

Table 111. Yposkesi Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 112. Yposkesi Recent Development

Table 113. Flash Therapeutics Company Detail

Table 114. Flash Therapeutics Business Overview

Table 115. Flash Therapeutics Viral Vector CDMOProduct

Table 116. Flash Therapeutics Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 117. Flash Therapeutics Recent Development

Table 118. VIVEBiotech Company Detail

Table 119. VIVEBiotech Business Overview

Table 120. VIVEBiotech Viral Vector CDMOProduct

Table 121. VIVEBiotech Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 122. VIVEBiotech Recent Development

Table 123. Miltenyi Bioindustry Company Detail

Table 124. Miltenyi Bioindustry Business Overview

Table 125. Miltenyi Bioindustry Viral Vector CDMOProduct

Table 126. Miltenyi Bioindustry Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 127. Miltenyi Bioindustry Recent Development

Table 128. Genezen Company Detail

Table 129. Genezen Business Overview

Table 130. Genezen Viral Vector CDMOProduct

Table 131. Genezen Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 132. Genezen Recent Development

Table 133. Miltenyi Biotec Company Detail

Table 134. Miltenyi Biotec Business Overview

Table 135. Miltenyi Biotec Viral Vector CDMOProduct

Table 136. Miltenyi Biotec Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 137. Miltenyi Biotec Recent Development

Table 138. Exthera Company Detail

Table 139. Exthera Business Overview

Table 140. Exthera Viral Vector CDMOProduct

Table 141. Exthera Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 142. Exthera Recent Development

Table 143. Catalent Company Detail

Table 144. Catalent Business Overview

Table 145. Catalent Viral Vector CDMOProduct

Table 146. Catalent Revenue in Viral Vector CDMO Business (2017-2022) & (US$ Million)

Table 147. Catalent Recent Development

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Viral Vector CDMO Market Share by Type: 2021 VS 2028

Figure 2. IIT Grade Features

Figure 3. IND Grade Features

Figure 4. Clinical Trial Grade Features

Figure 5. Commercial Production Grade Features

Figure 6. Global Viral Vector CDMO Market Share by Application in 2021 & 2028

Figure 7. Biopharmaceutical Company Case Studies

Figure 8. Academic Scientific Research Institution Case Studies

Figure 9. Viral Vector CDMO Report Years Considered

Figure 10. Global Viral Vector CDMO Market Size (US$ Million), Year-over-Year: 2017-2028

Figure 11. Global Viral Vector CDMO Market Size, (US$ Million), 2017 VS 2021 VS 2028

Figure 12. Global Viral Vector CDMO Market Share by Region: 2021 VS 2028

Figure 13. Global Viral Vector CDMO Market Share by Players in 2021

Figure 14. Global Top Viral Vector CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector CDMO as of 2021)

Figure 15. The Top 10 and 5 Players Market Share by Viral Vector CDMO Revenue in 2021

Figure 16. North America Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 17. North America Viral Vector CDMO Market Share by Country (2017-2028)

Figure 18. United States Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 19. Canada Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 20. Europe Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 21. Europe Viral Vector CDMO Market Share by Country (2017-2028)

Figure 22. Germany Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 23. France Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 24. U.K. Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 25. Italy Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 26. Russia Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 27. Nordic Countries Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 28. Asia-Pacific Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 29. Asia-Pacific Viral Vector CDMO Market Share by Region (2017-2028)

Figure 30. China Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 31. Japan Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 32. South Korea Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 33. Southeast Asia Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 34. India Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 35. Australia Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 36. Latin America Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 37. Latin America Viral Vector CDMO Market Share by Country (2017-2028)

Figure 38. Mexico Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 39. Brazil Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 40. Middle East & Africa Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 41. Middle East & Africa Viral Vector CDMO Market Share by Country (2017-2028)

Figure 42. Turkey Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 43. Saudi Arabia Viral Vector CDMO Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 44. Thermo Fisher Scientific Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 45. GenScript ProBio Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 46. Hillgene Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 47. Charles River Laboratories Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 48. Ubrigene Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 49. Obio Technology (shanghai) Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 50. Genesail Biotech (Shanghai) Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 51. WuXi ATU Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 52. Porton Advanced Solutions Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 53. Pharmaron Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 54. Asymchem Laboratories (Tianjin) Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 55. Merck Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 56. VectorBuilder Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 57. Yposkesi Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 58. Flash Therapeutics Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 59. VIVEBiotech Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 60. Miltenyi Bioindustry Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 61. Genezen Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 62. Miltenyi Biotec Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 63. Exthera Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 64. Catalent Revenue Growth Rate in Viral Vector CDMO Business (2017-2022)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Global Viral Vector CDMO Market Research Report 2022

Published Date: December 2022

Report Code: QYRE-Auto-4A12824

Global Viral Vector CDMO Market Research Report 2022

FEATURED COMPANIES

Viral Vector CDMO Market

By Company

By Type

By Application

By Region

FEATURED COMPANIES

RELATED REPORTS

$5800

Enterprise User

$5800

Enterprise User

$5800

Enterprise User

$8000

Enterprise User